Current Issue : January - March Volume : 2021 Issue Number : 1 Articles : 5 Articles
Background: The impact of Malassezia yeasts on skin mycobiome and health has received considerable attention\nrecently. Pityriasis versicolor (PV), a common dermatosis caused by Malassezia genus worldwide, is a manifestation of\ndysbiosis. PV can be associated with hyper- and/or hypopigmented skin lesions. This disease entity is characterized\nby high percentage of relapses, which demands a proper antifungal therapy that is based on unambiguous species\nidentification and drug susceptibility testing.\nCase presentation: Comprehensive analysis of PV case in man presenting simultaneously hyper- and\nhypopigmented skin lesions was performed. Conventional and molecular diagnostic procedures revealed Malassezia\nfurfur and Malassezia sympodialis, respectively as etiological agents of skin lesions observed. Susceptibility tests\nshowed significantly lowered sensitivity of M. furfur cells to fluconazole. Based on susceptibility profiles local\nantifungal therapy with drugs characterized by entirely different mechanism of action was included.\nConclusions: Our study indicates that cases of PV represented by two types of skin lesions in one patient may be\nassociated with distinct Malassezia species. Moreover, as observed in this case, each of the isolated etiological\nagents of PV may differ significantly in susceptibility to antifungals. This can significantly complicate the treatment\nof dermatosis, which by definition is associated with a significant percentage of relapses. In the presented case\nlocalized topical treatment was sufficient and successful while allowing maintaining the physiological mycobiome....
Background: Although the majority of rashes in the diaper area are caused by irritation from urine and feces,\nirritant diaper dermatitis; IDD, there are some less common but potentially serious cutaneous eruptions associated\nwith systemic diseases that should not be discounted.\nMethods: This prospective descriptive study aimed to explore variation in cutaneous disease in the diaper area. It\nwas conducted as a prospective descriptive study between October 2016 and November 2019 in the pediatric\ndepartment of a tertiary-level hospital.\nResults: Three hundred consecutive patients with rashes in the diaper area were enrolled. The most common\ndiagnosed was IDD (125 cases; 41.7%), followed by rashes exacerbated by the diaper (101 cases; 33.67%) and nondiaper-\nrelated rashes (74 cases; 24.67%).\nConclusions: Our finding suggests that when diagnosing rashes that occur in the diaper area, general pediatricians\nshould consider, in addition to IDD, the possibility of less-common conditions. The simultaneous presence of cutaneous\nlesions at other sites was linked to diagnoses of systemic diseases other than IDD, ......................
Background: Abnormalities of facial pigmentation, or facial melanoses, are a common presenting complaint in\nNepal and are the result of a diverse range of conditions.\nObjectives: The objective of this study was to determine the frequency, underlying cause and impact on quality of\nlife of facial pigmentary disorders among patients visiting the Department of Dermatology and Venereology, Nepal\nMedical College and Teaching Hospital (NMCTH) over the course of one year.\nMethods: This was a cross-sectional study conducted at the Department of Dermatology and Venereology, NMCT\nH. We recruited patients with facial melanoses above 16 years of age who presented to the outpatient department.\nClinical and demographic data were collected and all the enrolled participants completed the validated Nepali\nversion of the Dermatology Life Quality Index (DLQI).\nResults: Between January 5, 2019 to January 4, 2020, a total of 485 patients were recruited in the study. The most\ncommon diagnoses were melasma (166 patients) and post acne hyperpigmentation (71 patients). Quality of life\nimpairment was highest in patients having melasma with steroid induced rosacea-like dermatitis...........................
Background: Specific species of ceramides (Cer), major constituents of lipids in the stratum corneum (SC), are\ndecreased and are correlated with SC barrier and water-holding functions in the skin of patients with atopic\ndermatitis (AD) or psoriasis (Pso). However, possible correlations between Cer subclass ratios and skin properties in\nbarrier-disrupted skin and in healthy skin remain unclear. The objective of this study was to identify a new marker\nto evaluate skin properties and epidermal differentiation in SC not only in barrier-disrupted skin but also in healthy\nskin.\nMethods: The Cer subclass ratios in the SC of healthy control subjects and in patients with AD or Pso were\nevaluated. Correlations with candidate markers and facial skin features of healthy Japanese females (20â??74 years old,\nn = 210) were investigated. Variations of markers during epidermal differentiation were studied in human epidermis\nand in cultured keratinocytes.\nResults: The ratios of Cer [NP]/[NS], Cer [NH]/[NS], Cer [NP]/[AS], Cer [NH]/[NS], Cer [NDS]/[AS], Cer [AH]/[AS] and\nCer [EOP]/[AS] showed significant differences between non-lesional skin of AD patients and normal skin of healthy\ncontrol subjects, as well as Pso patients and their healthy control subjects. The Cer [NP]/[NS] ratio was correlated\nwith SC functional parameters (transepidermal water loss and capacitance) and with skin appearance (texture,\nscaling and color) even in the cheek skin of healthy female subjects. The Cer [NP]/[NS] ratio in the SC was\napproximately 18-times higher than in living keratinocytes, and it increased as they differentiated.\nConclusions: The Cer [NP]/[NS] ratio in the SC is a potential marker for skin properties and epidermal differentiation\nin barrier-disrupted skin as well as in healthy skin....
Background: Dupilumab, targeting the interleukin-4allpha receptor and inhibiting the action of interleukin-4 and\ninterleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data\non long-term effects and safety among patients with severe atopic dermatitis treated with dupilumab. Weight gain\nwas observed among patients treated with dupilumab in our clinic. The aim was to describe weight change in\na cohort study of patients with severe atopic dermatitis treated with dupilumab from baseline to follow-up after\n12 months, and to analyze if weight change was associated with effect of treatment, reported appetite, and/or\ndisturbed night sleep due to itching.\nMethods: All patients with atopic dermatitis receiving systemic treatment at the Unit of Dermatology, Karolinska\nUniversity Hospital, have been registered and monitored consecutively since January 2017. This cohort constituted\nall patients who started treatment on dupilumab or methotrexate between 10 January 2017 and 30 June 2019 with\nat least 6 months of follow-up within the study period............................
Loading....